Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Recurrence 4Breast Neoplasms 4Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Colorectal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Brain Neoplasms 1Alopecia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Immunoconjugates × Clear all
NCT07052760 2026-04-29

Imaging of Solid Tumors Using DLL3 SPECT

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

MBrace Therapeutics

Phase 1/2 Recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡